The purpose of this project was to identify and abstract data from randomized controlled trials (RCTs) of posttraumatic stress disorder (PTSD) interventions to support the development of a publicly accessible data repository by the National Center for Posttraumatic Stress Disorder.

The 2019 Report and Evidence Tables (Appendix E & F) are included in the downloadable .zip file. For more information, visit AHRQ's page, and look under "Previous Versions" tab: https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-treatment/research

The PTSD-Repository is a comprehensive database of PTSD trials. The PTSD-Repository allows clinical, research, education, and policy stakeholders to understand current research on treatment effectiveness and harms, and enable informed decisions about future research, mental health policy, and clinical care priorities. This report updates the studies and variables included in the PTSD-Repository to include recently published trials, interventions targeting comorbid PTSD/SUD (substance use disorder), variables related to comorbidities such as suicide and SUDs, and risk of bias (ROB) assessment.

The Comparative Effectiveness Review (Update Report) and Evidence Tables (Appendix E, F-1, & G-1) are included in the downloadable .zip file. For more information, visit AHRQ's page, and open the "Previous Versions" tab: https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-non-pharm-treatment/research

The U.S. Department of Veterans Affairs (VA) has established a long-term partnership to commission AHRQ to utilize its Evidence-based Practice Centers to develop update reviews to inform the VA’s PTSD-Repository – a publicly accessible clinical trials database maintained by the National Center for PTSD (NCPTSD).

The 2022 Report and Evidence Tables (Appendix F, G1, & G2-3) are included in the downloadable .zip file. For more information, visit AHRQ's page: https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-treatment/research